CN110464736A - A kind of application of composition, hydrogen physiological saline for treating bladder cancer - Google Patents
A kind of application of composition, hydrogen physiological saline for treating bladder cancer Download PDFInfo
- Publication number
- CN110464736A CN110464736A CN201910845745.0A CN201910845745A CN110464736A CN 110464736 A CN110464736 A CN 110464736A CN 201910845745 A CN201910845745 A CN 201910845745A CN 110464736 A CN110464736 A CN 110464736A
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- physiological saline
- bladder cancer
- composition
- bladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application of the composition, hydrogen physiological saline that the invention discloses a kind of for treating bladder cancer, the composition include: hydrogen physiological saline and chemotherapeutic；The chemotherapeutic is one of cis-platinum, adriamycin, hydroxycamptothecin, pirarubicin, epirubicin, gemcitabine or a variety of.Hydrogen physiological saline drug solution is more significant to inhibit external growth of bladder cancer cells, promotes apoptosis of tumor cells.And the exogenous hydrogen of intake is breathed or drinks or inject, histocompatbility is good, safety, few side effects, even if excessive, can also be excreted by breathing, not remained.
Description
Technical field
The present invention relates to pharmaceutical technology field more particularly to a kind of compositions for treating bladder cancer, hydrogen physiology
The application of salt water.
Background technique
Bladder cancer refers to the malignant tumour occurred in bladder mucosa, is the most common malignant tumour of urinary system, and
One of big kinds of tumor of whole body ten.Bladder cancer can betide any age, even children.Its disease incidence increases with the age and is increased
Add, high incidence age 50~70 years old, male bladder cancer morbidity is 3~4 times of women." urinary system and male are raw by WHO in 2004
Grow organ tumor pathology and science of heredity " in the classification of urinary tract system tumor histology the histological type of bladder cancer include urinary urine bladder
Road epithelioma, squamous cell carcinoma of bladder, adenocarcinoma of bladder, other rare also bladder clear cell carcinomas, bladder small cell carcinoma, wing
Guang class cancer.One of the most common is Urothelial Carcinoma of Bladder, accounts for about 90% or more of bladder cancer patients sum, usually said wing
Guang cancer just refers to Urothelial Carcinoma of Bladder.
Urothelial Carcinoma of Bladder is divided into non-Myometrial involvement bladder transitional cell carcinoma and Myometrial involvement bladder transitional cell carcinoma.Non- muscle layer
Wellability bladder transitional cell carcinoma patient mostly uses underwent transurethral resection of bladder tumor, postoperative to prevent to recur with bladder instillation to treat.Flesh
Layer wellability bladder transitional cell carcinoma and bladder squamous carcinoma, adenocarcinoma patients mostly use radial cystectomy art to treat, some patients can use
Partial cystectomy treatment.Myometrial involvement bladder transitional cell carcinoma patient can also first carry out new adjuvant chemotherapy+operative treatment side
Method.For metastatic bladder cancer based on chemotherapy, common chemotherapy regimen has M-VAP (methotrexate (MTX)+vinblastine+adriamycin+suitable
Platinum) and GC (gemcitabine+cis-platinum) and MVP (methotrexate (MTX)+vinblastine+cis-platinum) scheme, the effective percentage of chemotherapy is 40%~
65%.On Irrigation of Bladder Chemotherapy belongs to one kind of intracavitary chemotherapy.Doctor is injected chemotherapeutics in bladder using catheter, retains one
After fixing time, patient drains urine naturally and completes.Different pharmaceutical retention time is different, it should be noted that retention time
It needs in strict accordance with specification, to reach the best perfusion curative effect of drug.
In the prior art, the side reaction of bladder cancer perfusion is main or some local inflammations, patient compare after chemotherapy
It is easy to produce cystitis, general infusion has the symptom of apparent urine urgency-frequency for one to two days, and has when urination
Urodynia symptom, by cystoscopy it can be seen that the mucous membrane of urinary bladder of patient has extensive oedema.Bladder cancer perfusion may also lead to
Serious blood urine needs to postpone perfusion therapy once there are many generation patient's blood urine using the patient of Intravesical BCG, this
Sample can enter circulation to avoid tubercle bacillus, once not so tubercle bacillus invades, or even can cause the serious of septicemia and shock
Consequence.The case where bladder cancer perfusion sometimes also will appear systemic side effect.Had using the bladder cancer patients of Intravesical BCG
When have a fever, and can low-heat, or even have the symptom of different degrees of night sweat, and patient has the disease of DOMS
Shape, these are slight tubercle bacillus affection symptoms.
Therefore, the existing technology needs to be improved and developed.
Summary of the invention
The technical problem to be solved in the present invention is that in view of the above drawbacks of the prior art, provides and a kind of treat bladder cancer
Composition, hydrogen physiological saline application, it is intended to solve the problems, such as in the prior art bladder cancer perfusion side effect it is big.
The technical proposal for solving the technical problem of the invention is as follows:
It is a kind of for treating the composition of bladder cancer, wherein include: hydrogen physiological saline and chemotherapeutic；The chemotherapeutic is
One of cis-platinum, adriamycin, hydroxycamptothecin, pirarubicin, epirubicin, gemcitabine are a variety of.
The composition for being used to treat bladder cancer, wherein the concentration of hydrogen is 0.2ppm- in the hydrogen physiological saline
Saturation.
The composition for being used to treat bladder cancer, wherein the concentration of hydrogen is 0.8ppm in the hydrogen physiological saline.
The composition for being used to treat bladder cancer, wherein the hydrogen physiological saline is prepared using following steps:
Hydrogen is passed through after physiological saline and dispenses closed and is saved at 4 DEG C of normal pressure.
The composition for being used to treat bladder cancer, wherein the final concentration of 1mg/mL of epirubicin, gemcitabine
Final concentration of 20mg/mL.
The composition for being used to treat bladder cancer, wherein the composition is injection or perfusion liquid.
A kind of application of hydrogen physiological saline in preparation bladder cancer perfusion therapy drug.
The application, wherein the concentration of hydrogen is 0.2ppm- saturation in the hydrogen physiological saline.
The application, wherein the concentration of hydrogen is 0.8ppm in the hydrogen physiological saline.
The application, wherein injection or perfusion liquid is made in the drug.
The utility model has the advantages that hydrogen physiological saline drug solution is more significant to inhibit external growth of bladder cancer cells, promote tumour thin
Born of the same parents' apoptosis.And the exogenous hydrogen of intake is breathed or drinks or inject, histocompatbility is good, safety, few side effects, even if mistake
Amount can also be excreted by breathing, not remained.
Detailed description of the invention
Fig. 1 is to lead to hydrogen saturation time figure in the present invention in physiological saline.
Fig. 2 is hydrogen diffusivity rates figure in the present invention.
Fig. 3 be in the present invention hydrogen saturated saline solution drug solution to bladder cancer cell EJ growth effect figure.
Fig. 4 be in the present invention hydrogen saturated saline solution drug solution to bladder cancer cell T24 growth effect figure.
Fig. 5 is that different logical hydrogen times obtained hydrogen-rich physiological saline drug solutions grow shadow to bladder cancer cell EJ in the present invention
Ring figure.
Fig. 6 is that different logical hydrogen times obtained hydrogen-rich physiological saline drug solutions grow bladder cancer cell T24 in the present invention
Influence diagram.
Fig. 7 is three groups of orthotopic bladder cancer BALB/c nude mouse tumor position fluorescence imaging figures in the present invention.
Fig. 8 is that mouse tumor locus fluorescence carries out quantitative statistics figure in the present invention.
Fig. 9 is the corresponding weight of three groups of mouse tumors in the present invention after the treatment of surrounding.
Figure 10 is the photo that three groups of mouse dissect tumour in the present invention.
Specific embodiment
To make the objectives, technical solutions, and advantages of the present invention clearer and more explicit, right as follows in conjunction with drawings and embodiments
The present invention is further described.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, and do not have to
It is of the invention in limiting.
Please refer to Fig. 1-Figure 10, the present invention provides a kind of for treating some implementations of the composition of bladder cancer
Example.
Of the invention is a kind of for treating the composition of bladder cancer, comprising: hydrogen physiological saline and chemotherapeutic；The chemotherapeutic
For one of chemotherapeutics such as cis-platinum, adriamycin, hydroxycamptothecin, pirarubicin, epirubicin, gemcitabine or a variety of.
In a preferred embodiment of the present invention, the hydrogen physiological saline is prepared using following steps:
Hydrogen is passed through after physiological saline and dispenses closed and is saved at 4 DEG C of normal pressure.
Specifically, hydrogen hydrotropy need to be reached saturation solubility by the composition in sterile saline, be sub-packed in aluminium
The regular dosage forms such as injection are made in container or use the current existing system of hydrogen making machine/hydrogen gas tank.Hydrogen in hydrogen physiological saline used
Gas content is not less than 0.2ppm, that is to say, that the concentration of hydrogen is 0.2ppm- saturation in hydrogen physiological saline, raw to be saturated hydrogen
It is best to manage brine strength, about 0.8ppm.
The final concentration of 0.5-2mg/mL of epirubicin, gemcitabine are final concentration of in a preferred embodiment of the present invention
10-30mg/mL, specifically, the final concentration of 1mg/mL of epirubicin, the final concentration of 20mg/mL of gemcitabine.Cis-platinum is dense eventually
Degree is 1-30mg/mL, the final concentration of 0.5-20mg/mL of adriamycin, the final concentration of 1-30mg/mL of hydroxycamptothecin.
In a preferred embodiment of the present invention, the composition is injection or perfusion liquid.Specifically, injection can
To be injected by syringe, perfusion liquid can be irrigated by catheter.
The present invention also provides a kind of preferred embodiments of the application of hydrogen physiological saline:
The application of a kind of hydrogen physiological saline in preparation bladder cancer perfusion therapy drug in the embodiment of the present invention.
In a preferred embodiment of the present invention, the concentration of hydrogen is 0.2ppm- saturation, tool in the hydrogen physiological saline
Body is as described above.
In a preferred embodiment of the present invention, the concentration of hydrogen is 0.8ppm in the hydrogen physiological saline, specifically such as
It is upper described.
In a preferred embodiment of the present invention, injection or perfusion liquid is made in the drug, as detailed above.
In a preferred embodiment of the present invention, the hydrogen physiological saline is prepared using following steps:
Hydrogen is passed through after physiological saline and dispenses closed and is saved at 4 DEG C of normal pressure, as detailed above.
Specific embodiment
The preparation of hydrogen physiological saline: using hydrogen making machine or hydrogen gas tank ventilation 1h, pure hydrogen is dissolved in sterile saline
In to saturation state, dispense it is closed is stored in medical centrifugal, 4 degrees Celsius of normal pressure preservations.
Further, hydrogen is passed into physiological saline with different durations, hydrogen contains in physiological saline after the logical hydrogen of detection
Amount, and reach hydrogen and be saturated duration used, concrete outcome is as shown in Figure 1.After hydrogen content reaches saturation in physiological saline,
Stop logical hydrogen, detect hydrogen content in physiological saline reduces curve at any time, and concrete outcome is as shown in Figure 2.In physiological saline
After logical hydrogen time 5min, hydrogen content keeps stablizing in solution, reaches 0.8ppm, and content is maintained at 0.6ppm in 6 hours
More than, that is to say, that the composition is used by the way of ready-to-use, when needing to penetrate using injection or filling, first configures hydrogen
Then hydrogen physiological saline is mixed into chemotherapeutic by physiological saline, then injected or filled and penetrated.
The solution such as clinical chemotherapy drug such as epirubicin, gemcitabine are configured using hydrogen physiological saline, wherein the soft ratio of table
The final concentration of 1mg/mL of star, the final concentration of 20mg/mL of gemcitabine can also use other clinical chemotherapy drugs here certainly,
Such as cis-platinum, adriamycin, hydroxycamptothecin.Control group solution then utilizes Normal Saline, and (Normal Saline here is
Referring to the physiological saline that uses of general medical, do not carry out the operation for being passed through hydrogen) dilution epirubicin, gemcitabine is to identical dense
Degree.
Bladder cancer cell EJ, T24 is cultivated to 90% fusion.Every kind of cell is separately added into isometric hydrogen saturated saline solution
Drug solution and control group solution are cultivated, and 37 degrees Celsius, 5%CO2Cultivate 12h.It is grown using CCK8 method detection cell
Situation.Apoptosis by Flow Cytometry situation is utilized simultaneously, and concrete outcome is as shown in Figure 3 and Figure 4.
Guang cancer cell T24, EJ is spread into 96 orifice plates, culture to logarithmic growth phase with the density of 6000 cells/wells.With not hydrogeneous
As a control group, difference leads to hydrogen duration to the drug solution processing group (gemcitabine: 20mg/mL, epirubicin: 1mg/mL) of gas
Drug solution processing group is experimental group, processing culture cell 12h.Cell proliferative conditions, concrete outcome are detected using CCK8 method
As shown in Figure 5 and Figure 6.After Cell proliferation results show logical hydrogen 5min, bladder after the processing of hydrogen saturated saline solution drug solution
Cancer cell survival rate significantly reduces.
Bladder cancer cell T24, EJ is with 1 × 105The density of cells/well spreads 6 orifice plates, to be grown to logarithmic phase, with not hydrogeneous
As a control group, the drug solution processing group of hydrogen saturation is experimental group, processing culture cell to the drug solution processing group of gas
12h.Culture supernatant, and vitellophag are collected, Annexin V-FITC/PI dyeing is carried out after cell is collected by centrifugation, using stream
Formula cell art detects apoptosis rate.
Bladder cancer was the foundation of model originally: luciferase label is carried out to bladder cancer cell line T24 with slow-virus transfection method,
Healthy female BALB/c nude mice is anaesthetized, exposure bladder is dissected, cell solution is injected into mouse bladder wall with insulin needle,
It sews up a wound and continues to raise, be monitored using growing state of the small animal living body imaging system to tumour, specifically such as Fig. 7 institute
Show.
Administration mode: female BAl BIc/c nude mice of 16~18g of weight is chosen as experimental subjects, is randomly divided into three groups, room
Temperature 22~26 DEG C at raise, ad lib water inlet, 12 hours illumination/dark, daily by measure weight be administered.Wherein, control group
Orthotopic bladder cancer BALB/c nude mice, irrigation of bladder physiological saline (100 μ L//week) for 4 weeks.Chemotherapeutic prevention group original position wing
Guang cancer BALB/c nude mice, irrigation of bladder physiological saline+chemotherapeutic (100 μ L//week) for 4 weeks.Hydrogen treating group orthotopic bladder
Cancer BALB/c nude mice, irrigation of bladder physiological saline+chemotherapeutic+hydrogen (100 μ L//week) for 4 weeks.Per urethra irrigation of bladder,
Infusion time 1h, once a week.
Tumor monitoring: (the three groups of original position wing after four weeks of (three groups of orthotopic bladder cancer BALB/c nude mices) and experimental endpoints before experiment
Guang cancer BALB/c nude mice) growing state of tumour is monitored using small animal living body imaging system, it takes pictures.It is living using IVIS
Body imaging specialty analysis software quantifies the fluorescence of its tumor locus, and the growth of BALB/c nude mouse tumor is big between comparing three groups
It is small.From, as can be seen that physiological saline+chemotherapeutic+hydrogen (experimental group) effect is best after 4 weeks, tumour is eliminated in Fig. 7-Fig. 9
At most, fluorescence intensity is minimum, and weight is minimum；The effect of physiological saline+chemotherapeutic (control group) is taken second place；And physiological saline (blank
Group) effect it is worst, tumour eliminates minimum, fluorescence intensity highest, and weight is maximum.
Tumor weight: experimental endpoints (three groups of orthotopic bladder cancer BALB/c nude mices after four weeks) dissect mouse, take out
Bladder region tumors, are weighed and are taken pictures with electronic balance, and BALB/c nude mouse tumor grows size between comparing three groups.Physiology salt
Water+chemotherapeutic+hydrogen (experimental group) effect is best, and the diameter of tumour is minimum, about 4mm；(the control of physiological saline+chemotherapeutic
Group) effect take second place, the diameter of tumour is about 6mm；The effect of physiological saline (blank group) is worst, and the diameter of tumour is maximum, about
For 11mm.
Conclusion:
Compared to independent medication control group, hydrogen saturated saline solution drug solution is more significant to inhibit external bladder cancer thin
Intracellular growth promotes apoptosis of tumor cells.
Compared to independent medication and blank control group, hydrogen saturated saline solution drug solution is more significant to inhibit internal wing
The growth of Guang cancer.
It is proved by vitro test, hydrogen is alternative in the solution to neutralize hydroxy radical and nitrous acid anion, then
The two is the main medium for leading to cell oxidative damage, not yet finds endogenous specificity in vivo at present and removes approach.Therefore
Think, the basis of the drug-induced inflammation of hydrogen treating On Irrigation of Bladder Chemotherapy is selective antioxidation.With conventional medicament phase
Than hydrogen applications have high-definition advantage in pharmaceutical technology field: firstly, hydrogen reduction is weak, only with active strong and toxicity
Strong radical reaction, and have the function of that important biomolecule, toxicity and the lower free radical of activity influence less to other, this is
The selective antioxidation of hydrogen.Secondly, hydrogen is a kind of small molecule, it can easily be diffused into other medicines and be difficult to
Organ, the cell and crganelle of arrival, or even site of tissue damage is reached before revascularization, play biological effect.Again,
Normal flora is all generating hydrogen daily in humans and animals gastrointestinal tract, can be absorbed by organisms metabolism, and by breathing or drinks
Or the exogenous hydrogen of injection intake, histocompatbility is good, safety, few side effects, even if excessive, can be also discharged by breathing
In vitro, it does not remain.Finally, hydrogen resources are abundant, prepare convenient, cheap, asepsis environment-protecting.
In conclusion a kind of application of composition, hydrogen physiological saline for treating bladder cancer provided by the present invention, institute
Stating composition includes: hydrogen physiological saline and chemotherapeutic；The chemotherapeutic is one of epirubicin or gemcitabine or a variety of.
Hydrogen physiological saline drug solution is more significant to inhibit external growth of bladder cancer cells, promotes apoptosis of tumor cells.And it breathes or drinks
With or injection intake exogenous hydrogen, histocompatbility is good, safety, few side effects, even if excessive, can also pass through breathing row
It is external out, do not remain.
It should be understood that the application of the present invention is not limited to the above for those of ordinary skills can
With improvement or transformation based on the above description, all these modifications and variations all should belong to the guarantor of appended claims of the present invention
Protect range.
Claims (10)
1. a kind of for treating the composition of bladder cancer characterized by comprising hydrogen physiological saline and chemotherapeutic；The chemotherapy
Medicine is one of cis-platinum, adriamycin, hydroxycamptothecin, pirarubicin, epirubicin, gemcitabine or a variety of.
2. according to claim 1 for treating the composition of bladder cancer, which is characterized in that hydrogen in the hydrogen physiological saline
The concentration of gas is 0.2ppm- saturation.
3. according to claim 2 for treating the composition of bladder cancer, which is characterized in that hydrogen in the hydrogen physiological saline
The concentration of gas is 0.8ppm.
4. according to claim 1 for treating the composition of bladder cancer, which is characterized in that the hydrogen physiological saline uses
Following steps preparation:
Hydrogen is passed through after physiological saline and dispenses closed and is saved at 4 DEG C of normal pressure.
5. according to claim 1 for treating the composition of bladder cancer, which is characterized in that the epirubicin final concentration
For 1mg/mL, the final concentration of 20mg/mL of gemcitabine.
6. according to claim 1 for treating the composition of bladder cancer, which is characterized in that the composition is injection
Or perfusion liquid.
7. a kind of application of hydrogen physiological saline in preparation bladder cancer perfusion therapy drug.
8. application according to claim 7, which is characterized in that the concentration of hydrogen is 0.2ppm- in the hydrogen physiological saline
Saturation.
9. application according to claim 8, which is characterized in that the concentration of hydrogen is 0.8ppm in the hydrogen physiological saline.
10. application according to claim 7, which is characterized in that injection or perfusion liquid is made in the drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910845745.0A CN110464736A (en) | 2019-09-06 | 2019-09-06 | A kind of application of composition, hydrogen physiological saline for treating bladder cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910845745.0A CN110464736A (en) | 2019-09-06 | 2019-09-06 | A kind of application of composition, hydrogen physiological saline for treating bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110464736A true CN110464736A (en) | 2019-11-19 |
Family
ID=68515163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910845745.0A Pending CN110464736A (en) | 2019-09-06 | 2019-09-06 | A kind of application of composition, hydrogen physiological saline for treating bladder cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110464736A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616666A (en) * | 2021-08-24 | 2021-11-09 | 傅广波 | Use of sub-mucosal injection of gemcitabine into the bladder for the treatment of bladder cancer |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562361A (en) * | 2003-09-19 | 2005-01-12 | 沈周俊 | Compound pefusion for anti bladder cancer |
| CN105079025A (en) * | 2015-06-17 | 2015-11-25 | 泰山医学院 | Application of hydrogen saturated saline |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| CN107281214A (en) * | 2017-06-06 | 2017-10-24 | 北京工业大学 | Hydrogen molecule liquid/gas is preparing the application in suppressing tumor stem cell medicine |
| CN107929314A (en) * | 2016-10-13 | 2018-04-20 | 上海市同济医院 | A kind of hydrogeneous physiological saline and its preparation method and application |
| CN108707069A (en) * | 2018-07-06 | 2018-10-26 | 山西省肿瘤医院 | A kind of anti-bladder cancer compound and its application |
-
2019
- 2019-09-06 CN CN201910845745.0A patent/CN110464736A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562361A (en) * | 2003-09-19 | 2005-01-12 | 沈周俊 | Compound pefusion for anti bladder cancer |
| CN105079025A (en) * | 2015-06-17 | 2015-11-25 | 泰山医学院 | Application of hydrogen saturated saline |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| CN107929314A (en) * | 2016-10-13 | 2018-04-20 | 上海市同济医院 | A kind of hydrogeneous physiological saline and its preparation method and application |
| CN107281214A (en) * | 2017-06-06 | 2017-10-24 | 北京工业大学 | Hydrogen molecule liquid/gas is preparing the application in suppressing tumor stem cell medicine |
| CN108707069A (en) * | 2018-07-06 | 2018-10-26 | 山西省肿瘤医院 | A kind of anti-bladder cancer compound and its application |
Non-Patent Citations (4)
| Title |
|---|
| SHUJING WU ET AL: "Hydrogen-containing saline attenuates doxorubicin-induced heart failure in rats", 《PHARMAZIE》 * |
| XIAOYIN MENG ET AL: "Hydrogen‑rich saline attenuates chemotherapy‑induced ovarian injury via regulation of oxidative stress", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
| YE YANG ET AL: "Anti‑inflammatory and antitumor action of hydrogen via reactive oxygen species", 《ONCOLOGY LETTERS》 * |
| 郑心主编: "《肿瘤中西医结合预防与治疗》", 31 May 2018, 山东科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616666A (en) * | 2021-08-24 | 2021-11-09 | 傅广波 | Use of sub-mucosal injection of gemcitabine into the bladder for the treatment of bladder cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210267896A1 (en) | Formulations for treating bladder cancer | |
| CN114288278B (en) | Drug-loaded microalgae, preparation method and application thereof | |
| CN108653733A (en) | Polymer vesicle and the preparation of double load anthracene nucleus medicaments and photosensitizer with bubble formation function | |
| CN103520207A (en) | Targeting cisplatin sodium nano-alginate liposome | |
| CN109718208B (en) | Application of polysaccharide-modified nano-selenium complexes in the treatment of malignant ascites | |
| CN110464736A (en) | A kind of application of composition, hydrogen physiological saline for treating bladder cancer | |
| CN106267240B (en) | Isosulfur blue injection for lymphatic tracing and preparation method thereof | |
| CN106265722A (en) | The application in prevention and control of cancer of the ozone carburetion | |
| CN113616666A (en) | Use of sub-mucosal injection of gemcitabine into the bladder for the treatment of bladder cancer | |
| TWI296527B (en) | Radioactive aesenic-containing compounds and their uses in the treatment of tumors | |
| CN101507747B (en) | Preparation method of astragalus total-saponin sodium chloride injector | |
| CN110051734B (en) | A medicinal composition for anti-colitis-related colon cancer and its application | |
| WO2023207054A1 (en) | Use of ganoderma lucidum spore oil in preparing a drug for prolonging survival time of tumor patients | |
| CN104906145B (en) | Medical application of the Paecilomyces hepiali chen mutagenic strain PH40 in treatment diabetes | |
| CN111066728A (en) | Construction method of hyperglycemia animal model | |
| CN109394784A (en) | The screening model of anti-head-neck carcinoma tumour medicine | |
| Morere et al. | Cisplatin—5-fluorouracil in small cell lung cancer. A Phase II study in 109 patients | |
| CN116983310B (en) | Pharmaceutical composition for treating liver cancer and application thereof | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| US20100029590A1 (en) | Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt | |
| RU2691345C1 (en) | Method of treating rectal cancer | |
| CN107582564A (en) | A kind of medicine of targeted therapy thyroid cancer and preparation method thereof | |
| CN1771984B (en) | New use of extracellular polysaccharide of halophilous aphanothece | |
| RU2234962C2 (en) | Method for treating the cases of non-resectable pancreatic carcinoma | |
| TWI635860B (en) | Use of acridine derivatives for preparing pharmaceutical compositions for treating urothelial cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191119 |
|
| RJ01 | Rejection of invention patent application after publication |